Yes. Autoimmune disease can affect treatment safety, especially when medicines suppress your immune system or the disease has affected your organs. For stem-cell infusions or injections, your specialist needs to review disease activity, medicines, organ function, and the exact product and route. An autoimmune diagnosis alone does not establish whether treatment is suitable.
This article focuses on stem-cell treatment safety for people who already have an autoimmune disease, not whether stem cells can treat that disease.

Why autoimmune disease changes the safety question
Autoimmune diseases involve the immune system mistakenly attacking healthy tissue. NIAMS describes autoantibodies targeting the body’s own tissues. Examples include rheumatoid arthritis, lupus, Sjogren’s disease, scleroderma, and psoriasis. Their effects and treatments differ, so the diagnosis alone is not a safety assessment.Autoimmune diseases
Which treatment are you asking about
First distinguish a blood-forming stem-cell transplant from an MSC infusion or injection. Donor versus your own cells is a separate distinction within a treatment, not a third treatment category.
- Blood-forming stem-cell transplantation sends cells through a vein to the bone marrow after strong chemotherapy or radiation.Stem cell transplant Doctors use it for selected blood cancers, blood disorders, and some autoimmune disorders.Stem cell transplant It is a separate decision from clinic infusions. Use of a transplant procedure does not establish approval of a different cell product for autoimmune care.Important patient and consumer information about regenerative medicine therapies
- Clinics also offer mesenchymal stromal cell infusions or injections. For most conditions, these are still experimental, not established care.Important patient and consumer information about regenerative medicine therapies
- Products made from another person’s cells raise extra questions about matching and immune reactions.
The National Cancer Institute lists problems linked to the full transplant process with high-dose chemotherapy or radiation, not the cell infusion alone. They include bleeding, infection, fatigue, infertility, organ damage, and second cancers.Stem cell transplant
Do not assume that every MSC product is unapproved, or that an approval covers all MSC treatments. On December 18, 2024, the FDA approved Ryoncil, a donor bone-marrow-derived MSC therapy, for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. That is a specific transplant complication, not a general autoimmune indication.Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host
The FDA warns that unapproved regenerative products have been associated with blindness, tumor formation, infections, unwanted immune responses, and cells growing where they should not. Ask about the approval status of the exact product for the exact proposed use.Important patient and consumer information about regenerative medicine therapies
What safety numbers can and cannot tell you
The studies below do not provide an autoimmune-specific complication rate for your proposed treatment. Assess any safety claim against the product, route, and patient group actually studied.
| Example | What was studied | What happened | What it means for you |
|---|---|---|---|
| Knee injections | 48 studies, 1,924 patients with knee osteoarthritis receiving stem-cell-based injections (bone marrow, fat-derived, cord-derived, and cultured preparations) | 12.3% had transient adverse events, about 1 in 8, most often swelling and injection-site pain lasting less than 4 weeks; no infection, sepsis, new tumor, embolism, or death was reported in the included short-term data39564419 | These knee-OA data do not establish the risk for an autoimmune patient receiving a different product, an intravenous infusion, or immunosuppressive medicines.39564419 |
| MSC administration and fever | 152 randomized trials including 9,228 MSC-treated individuals (autologous or donor cells from fat or bone marrow sources) reviewed as a 2024 systematic review on transient fever011574888X179799231023060734 | Fever after MSC administration was examined as the treatment-related event in that review011574888X179799231023060734 | Fever timing alone cannot distinguish an infusion reaction from infection. That difference matters a great deal when immunity is already suppressed |
Results also differed by preparation. Cord-derived injections (51.7% in that subgroup) and cultured fat-derived cells (29.5%) had more transient events than bone marrow cells and stromal vascular fraction in that dataset.39564419 The subgroups were small and counted events in different ways, so this is not a head-to-head ranking. Protocols, formulations, and timing also varied widely across studies.39564419
The knee review was not designed to establish safety in people with autoimmune disease; it does not show that every participant was free of autoimmunity. Absence of reported serious events in the included studies is not proof that serious or delayed complications cannot occur.39564419
How autoimmunity changes safety
Infection risk
Some autoimmune medicines suppress immune responses. NIAMS notes that many rheumatoid-arthritis medicines may increase infection risk, and that clinicians may monitor for infections and recommend vaccines. The effect depends on the drug and your circumstances, not simply on having an autoimmune diagnosis.Diagnosis treatment and steps to take
Any step that breaks the skin, collects tissue, grows cells, or puts a product into your body adds a chance of infection. The FDA names bacterial infections, including blood infections that can be life-threatening, and contamination during processing.Important patient and consumer information about regenerative medicine therapies
Organ involvement
Lupus can affect the kidneys, heart, lungs, blood cells, and brain.Autoimmune diseases Rheumatoid arthritis can also involve organs outside the joints, including the lungs and heart.Diagnosis treatment and steps to take Tell the team which organs your specialist has found to be affected.
- Poor kidney or liver function changes how the body clears drugs.
- Lung or heart involvement changes which anesthesia and infusion settings are safe.
- Ask whether current inflammation, anemia, or other blood-count abnormalities affect procedural safety or recovery.
- Tell the team about any past blood clot and the drugs used for it.
Disease activity and timing
Your specialist needs to distinguish an active flare from stable disease and from organ-threatening illness that needs urgent standard care.
New symptoms after treatment need assessment rather than an assumption that they are a flare or an expected infusion reaction. For an elective procedure, ask whether active infection, a recent flare, or a medication adjustment is a reason to postpone.
Medicines and timing
Do not stop or reduce immune-suppressing medicines on your own to qualify for cell treatment. Ask your prescribing specialist to coordinate any changes with the treating team; this article does not provide a stopping schedule.
Bring the full list to every visit:
- Drug names, doses, and how often you take them
- When each was started, and any recent changes
- Steroid history, including injections in the past months
- Recent antibiotics, antivirals, or antifungals
- Over-the-counter immune products, supplements, and vaccines
Ask the clinic for the product details in writing. This should include cell type and source, whether the cells are yours or from a donor, fresh or thawed, dose per administration, number of sessions, and how adverse events are monitored.
Donor cells
In a donor blood-forming stem-cell transplant, HLA matching helps reduce immune complications. Graft-versus-host disease means donor immune cells attack the recipient’s tissues. Matching reduces risk but does not remove it.Stem cell transplant
Do not transfer those transplant matching rules or complication rates directly to an MSC infusion. For an MSC product, ask for its own immune-reaction, infection, and infusion-monitoring information. Even the approved MSC product Ryoncil has warnings about acute infusion reactions, infectious-agent transmission, and ectopic tissue formation.Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host
Checks that decide your eligibility
Your specialist may use these records to assess suitability. They are not a universal testing protocol, and normal results do not establish that an unproven product is safe or effective.
| Area | What the doctor reviews |
|---|---|
| Diagnosis detail | Exact disease, how it was diagnosed, current activity, recent flares |
| Organs affected | Kidneys, lungs, heart, blood counts, nervous system |
| Medicines | Immunosuppressants, steroids, biologics, blood thinners, recent changes |
| Infection screen | Recent or ongoing infections, tuberculosis risk, hepatitis and HIV testing where relevant |
| Cancer and clot history | Prior cancers, prior clots, family and personal risk factors |
| Pregnancy and fertility | Pregnancy status, plans, and fertility effects of any intensive treatment |
| Procedure specifics | Cell type, source, processing, dose, route, anesthesia, follow-up plan |
If a provider says autoimmune disease “does not matter” without asking for these records, treat that as a warning sign rather than reassurance.
When to wait
Postpone elective timing
- Fever, active infection, or current treatment for a recent infection; ask the treating physician about timing rather than using antibiotic completion as an automatic clearance rule
- A recent autoimmune flare or a medication change your specialist is still adjusting
Seek urgent care now
- Chest pain, trouble breathing, leg swelling, or signs of a blood clot
- A hot, swollen, very painful joint with fever, which can signal joint infection
- New weakness, numbness, or loss of bladder or bowel control after a back procedure
- Swelling of the face or tongue, wheezing, or collapse after an injection or infusion
These situations need prompt in-person care. If breathing or consciousness is affected, call your local emergency number.
If you are considering Japan
Japan has a framework for submitting regenerative-medicine provision plans under the Act on the Safety of Regenerative Medicine. MHLW describes procedures before provision and rules for cell processing; submission is not a statement that a treatment will work for your autoimmune disease.Index Product marketing approval is a separate question: PMDA provides information on approved regenerative medical products. Check the named product, indication, and conditions of use, not simply a clinic’s statement that it is registered.0003
Before you travel, confirm the exact legal pathway, the exact product, what follow-up is included, and the itemized cost. Only licensed physicians decide eligibility. Coordination or translation support is not a substitute for that decision.
Prepare a consultation record
For example, if your arthritis feels controlled but you recently changed a biologic medicine, include both facts rather than writing only “my disease is stable.” Attach your specialist’s dated assessment and medicine list, and name the cell product and route being proposed. This is a preparation example, not a report of a treated patient.
Use the same record to ask who will assess new fever, swelling, or other symptoms after treatment, including after you return home. A support team can help organize information, but cannot provide medical clearance.
Questions to ask
- Given my exact autoimmune diagnosis and current activity, am I a candidate for this specific product and route — or should standard care come first?
- How do my current immunosuppressive medicines affect infection risk and timing?
- What infections and organ checks do you require before treatment?
- What are the known risks of this exact product, including infection, immune reaction, and procedure-site problems?
- How will you distinguish a disease flare from a treatment complication after the procedure?
- What follow-up is arranged when I return home, and who manages complications?
- What will this change about my existing autoimmune treatment — and who coordinates with my rheumatologist?
Bring dated blood counts, relevant imaging, the latest specialist note, and an agreed follow-up contact. Ask which additional tests are appropriate for your particular product and health history.
Considering treatment in Japan with an autoimmune condition? Ask how to submit your diagnosis, medicine list, and recent reports securely for a physician-led assessment. Patient support is not medical clearance.
The bottom line
Autoimmune disease can change treatment risk, but there is no single safety percentage that applies to everyone. Have your specialist review medicines, organ involvement, disease activity, and the exact cell product before deciding whether to proceed. Neither a clinic registration nor another patient group’s results replace that assessment.
References
- NIAMS — Autoimmune Diseases. https://www.niams.nih.gov/health-topics/autoimmune-diseases Last reviewed March 2023. Accessed 2026-11-02. Definitions, examples, and lupus organ involvement.
- NCI — Stem Cell Transplants in Cancer Treatment. https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant Accessed 2026-11-02. Transplant process, uses, matching, and risks; not MSC-clinic safety data.
- FDA — Important Patient and Consumer Information About Regenerative Medicine Therapies. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies Accessed 2026-11-01. Used here for unapproved-product risks, not as a current exhaustive list of approvals.
- FDA — Approval of Ryoncil for Steroid-refractory Acute Graft-versus-host Disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host December 18, 2024. Accessed 2026-11-02. United States; pediatric patients aged 2 months and older with the specified transplant complication.
- Riggle C. et al. — Complications of Stem Cell-Based Injections for Knee Osteoarthritis: A Systematic Review. https://pubmed.ncbi.nlm.nih.gov/39564419/ Accessed 2026-11-02. Human knee-OA studies; 48 studies, 1,924 patients; not an autoimmune-specific safety estimate. Heterogeneous preparations and follow-up; PubMed indexing alone does not establish quality.
- Wang Y. et al. — Transient Fever: The Sole Treatment-Related Adverse Event Associated with Mesenchymal Stromal Cells and Solid Clues from the Real World. https://doi.org/10.2174/011574888X179799231023060734 2024. Accessed 2026-11-01; bibliographic title checked 2026-11-02. Review size reused from the source record; not a universal safety guarantee or an autoimmune-specific risk estimate.
- NIAMS — Rheumatoid Arthritis: Diagnosis, Treatment, and Steps to Take. https://www.niams.nih.gov/health-topics/rheumatoid-arthritis/diagnosis-treatment-and-steps-to-take Accessed 2026-11-02. Medicines and infection risk, monitoring, vaccines, and extra-articular involvement; disease-specific context.
- MHLW — Regenerative, Cellular and Gene Therapies. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/saisei_iryou/index.html Accessed 2026-11-02. Japan; provision-plan procedures and cell-processing framework.
- PMDA — Regenerative Medical Products. https://www.pmda.go.jp/english/review-services/reviews/approved-information/0003.html Accessed 2026-11-02. Japan; approved-product information, distinct from provision-plan submission.
This article provides general information only and is not personal medical advice. Decisions about autoimmune treatment and any cell procedure should be made with a qualified physician who has your full medical history.




